A Magnesium Phosphate-Based Platform Alleviates Bone-Fat Imbalance for the Repair of Age-Related Osteoporotic Bone Defects.
Zhang X., Luo Y., Liu Y., Liu W., Zheng J., Gong C.
Animal Study, published in Biomedicines (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biomedicines (2026)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42351730
- DOI
- 10.3390/biomedicines14061302
Abstract (original English)
Background/Objectives : Osteoporosis poses significant obstacles as it causes an imbalance between osteoblasts and adipocytes, which results in the disruption of bone homeostasis. Although various magnesium-based scaffolds have been deployed for the treatment of osteoporotic bone defects, whether this can be achieved by alleviating bone-fat imbalance still requires further elucidation. Methods : We designed magnesium phosphate-based platforms (GMPCs), based on magnesium photopolymerized methacrylated gelatin (GelMA) and phosphate (K-struvite, MPC), and used them to deliver magnesium ions (Mg 2+ ) for alleviating bone-fat imbalance locally. Results : The in vivo results demonstrated that the GMPCs not only improved osteogenic behavior at the implanted site, but also reduced the proportion of adipose tissues in a femoral defect model in 18-month-old SD rats. Moreover, by promoting the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts in a concentration-dependent manner, GMPCs significantly reduced adipogenic differentiation in vitro. Also, 5GMPC demonstrated the best comprehensive biologic properties compared to other platforms. Conclusions : GMPCs have great potential in the treatment of age-related osteoporosis via the effective delivery of Mg 2+ .
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.